Real-world evidence demonstrates efficacy of hepatitis C treatment Epclusa®
New data presented at the International Liver Congress™ 2019 (10-14 April, Vienna, Austria) demonstrates efficacy of Epclusa® in treating hepatitis C.
Gilead Sciences, Inc. (CA, USA) has presented new data from ongoing assessment of real-world data on the efficacy of Epclusa® (sofosbuvir 400mg/velpatasvir 100mg) in the treatment of hepatitis C (HCV) genotype 1-6 treated across North America and the European Union. According to the presentation at the International Liver Congress™ 2019 (ILC), 98.5% of 5541 patients achieved SVR12, which indicates HCV was undetectable for 12 or more weeks post-treatment.
“To achieve the World Health Organization’s goal of eliminating HCV globally by 2030, we will require treatments that are highly effective and have simple dosing regimens with broad clinical utility,” said Alessandra Mangia, Chief of Liver Unit, IRCCS-Ospedale Casa Sollievo Della Sofferenza, San Giovanni Rotondo, Italy, who presented the data at the ILC 2019.
“This real-world analysis demonstrates that Epclusa can cure HCV patients irrespective of genotype or cirrhosis status, which is essential for implementing test and treat strategies in populations with HCV around the world.”
“As part of our ongoing commitment to patients living with viral hepatitis, we continue to research the roles of our HBV and HCV medicines across the broadest range of patient populations. These latest data demonstrate that the efficacy of our HCV medicines is consistent in clinical trials and in real-world settings, even in difficult-to-cure patients,” said John McHutchison, Chief Scientific Officer, Head of Research and Development, Gilead Sciences.